Warburg Glycomed has expressed keen interest in collaborating with NextGen in a recently signed letter of intent, and is confident that a mutually beneficial deal can be arranged.
Konstantinos Kardiasmenos, CEO of NextGen, said: “These collaboration discussions with Warburg Glycomed represent progress on fulfilling our business goal to form international collaboration agreements with specialty research organisations. An alliance with Warburg would strengthen both companies’s position to capture the phenomenal global market for therapeutic cancer agents.”